Pharma BD Deal Intelligence
Organon (NYSE: OGN) completed its acquisition of Dermavant Sciences (a Roivant subsidiary) on October 28, 2024, after announcing the definitive agreement on September 18, 2024. Deal value up to $1.2B: $175M upfront, $75M on FDA approval of VTAMA in atopic dermatitis, and up to $950M in commercial milestones, plus tiered royalties. The lead asset is VTAMA (tapinarof) cream, 1%, a first-in-class topical aryl hydrocarbon receptor (AhR) agonist approved for plaque psoriasis. The atopic dermatitis sNDA — the central catalyst of the deal thesis — was approved by the FDA on December 16, 2024 for adults and children 2 years and older (ahead of the extended March 12, 2025 PDUFA date), triggering the $75M AD-approval milestone and giving VTAMA the only non-steroidal topical label spanning both plaque psoriasis and atopic dermatitis.